Astellas, Boehringer Sue Impax For Prostate Drug Patent Infringement
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Moving in concert with the Japanese government's policy to toughen intellectual property rights protection, Astellas, jointly with Boehringer Ingelheim Pharmaceuticals, filed a patent infringement lawsuit in the United States against Impax Laboratories for Astellas' prostate treatment drug, the company announced July 22
You may also be interested in...
Astellas/Boehringer Get Flomax Market Exclusivity Extension Through Pediatric Study
Tokyo-based Astellas Pharma announced that U.S. marketing partner Boehringer Ingelheim has obtained six-month pediatric exclusivity for blockbuster benign prostate hyperplasia drug Flomax (tamsulosin). The Flomax substance patent expires in October, and the period of market exclusivity will now be extended to April 2010
Astellas/Boehringer Get Flomax Market Exclusivity Extension Through Pediatric Study
Tokyo-based Astellas Pharma announced that U.S. marketing partner Boehringer Ingelheim has obtained six-month pediatric exclusivity for blockbuster benign prostate hyperplasia drug Flomax (tamsulosin). The Flomax substance patent expires in October, and the period of market exclusivity will now be extended to April 2010
Eisai Wins Patent Lawsuit For Proton Pump Inhibitor AcipHex
TOKYO - In a decision that would bolster its underlying profit-making structure and spur its intellectual property protection policy, Eisai July 22 said it won a patent lawsuit for its proton pump inhibitor AcipHex, one of its two leading global pharmaceutical products, in the U.S